Cardiff Oncology Inc at JMP Securities Hematology Oncology Summit (Virtual) Transcript
Welcome to Day 2 of our annual JMP Hematology and Oncology Conference. My name is Silvan Türkcan and I'm Senior Analyst covering precision medicines here at JMP Securities. It's my pleasure to host Mark Erlander, Chief Executive Officer of Cardiff Oncology. Thank you so much for joining us today.
Well, thank you, Silvan. I really appreciate the invite and the opportunity to tell everybody a little bit about what we're doing at Cardiff Oncology.
True, yes. And obviously, it's a very important day for KRAS today, and you're forging ahead with onvansertib development in RAS-mutated tumors. So looking forward to your presentation.
Okay. All right. Well, let me get started then. What is the -- why would you want to invest in Cardiff Oncology? What's the what, where, and why? Really onvansertib, we've
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
